|
[1] TERRAULT NA,LOK ASF,McMAHON BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
|
|
[2] WANG CH,WEY KC,MO LR,et al. Current trends and recent advances in diagnosis,therapy,and prevention of hepatocellular carcinoma[J]. Asian Pac J Cancer Prev,2015,16(9):3595-3604.
|
|
[3] PAPATHEODORIDIS GV,LAMPERTICO P,MANOLAKOPOULOS S,et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:A systematic review[J]. J Hepatol,2010,53(2):348-356.
|
|
[4] PAPATHEODORIDIS GV,IDILMAN R,DALEKOS GN,et al.The risk of hepatocellular carcinoma decreases after the first 5years of entecavir or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology,2017,66(5):1444-1453.
|
|
[5] MARCELLIN P,HEATHCOTE EJ,BUTI M,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N Engl J Med,2008,359(23):2442-2455.
|
|
[6] YUEN MF,TANAKA Y,FONG DY,et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B[J]. J Hepatol,2009,50(1):80-88.
|
|
[7] WONG VW,CHAN SL,MO F,et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers[J]. J Clin Oncol,2010,28(10):1660-1665.
|
|
[8] YANG HI,YUEN MF,CHAN HL,et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACH-B):Development and validation of a predictive score[J]. Lancet Oncol,2011,12(6):568-574.
|
|
[9] JUNG KS,KIM SU,SONG K,et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy[J]. Hepatology,2015,62(6):1757-1766.
|
|
[10] PAPATHEODORIDIS G,DALEKOS G,SYPSA V,et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol,2016,64(4):800-806.
|
|
[11] KIM JH,KIM YD,LEE M,et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol,2018,69(5):1066-1073.
|
|
[12] LEE HW,AHN SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients[J]. World J Gastroenterol,2016,22(37):8314-8321.
|
|
[13] SEO YS,JANG BK,UM SH,et al. Validation of risk prediction models for the development of HBV-related HCC:A retrospective multi-center 10-year follow-up cohort study[J].Oncotarget,2017,8(68):113213-113224.
|
|
[14] KIM MN,HWANG SG,RIM KS,et al. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir[J]. Liver Int,2017,37(12):1788-1795.
|
|
[15] YIP TC,WONG GL,WONG VW,et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B[J]. J Hepatol,2020,72(5):847-854.
|
|
[16] CHEN CH,LEE CM,LAI HC,et al. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir[J]. Oncotarget,2017,8(54):92431-92441.
|
|
[17] SOHN W,CHO JY,KIM JH,et al. Risk score model for the development of hepatocellular carcinoma in treatment-nave patients receiving oral antiviral treatment for chronic hepatitis B[J]. Clin Mol Hepatol,2017,23(2):170-178.
|
|
[18] HSU YC,YIP TC,HO HJ,et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B[J]. J Hepatol,2018,69(2):278-285.
|
|
[19] KIM SU,SEO YS,LEE HA,et al. Validation of the CAMD score in patients with chronic hepatitis B virus infection receiving antiviral therapy[J]. Clin Gastroenterol Hepatol,2020,18(3):693-699. e1.
|
|
[20] PAPATHEODORIDIS GV,SYPSA V,DALEKOS GN,et al.Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B[J]. J Hepatol,2020,72(6):1088-1096.
|
|
[21] YANG HI,YEH ML,WONG GL,et al. Real-world effectiveness from the Asia Pacific rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis,2020,221(3):389-399.
|
|
[22] WONG GL,CHAN HL,MAK CW,et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis[J]. Hepatology,2013,58(5):1537-1547.
|
|
[23] PAPATHEODORIDIS GV,CHAN HL,HANSEN BE,et al. Risk of hepatocellular carcinoma in chronic hepatitis B:Assessment and modification with current antiviral therapy[J]. J Hepatol,2015,62(4):956-967.
|
|
[24] LEE MH,YANG HI,LIU J,et al. Prediction models of longterm cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients:Risk scores integrating host and virus profiles[J]. Hepatology,2013,58(2):546-554.
|
|
[25] LIN YJ,LEE MH,YANG HI,et al. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients[J]. PLo S One,2013,8(4):e61448.
|
DownLoad: